Bank Julius Baer & Co. Ltd, Zurich Clovis Oncology, Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$2.7 - $4.76 $10,800 - $19,040	-4,000 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$4.06 - $5.8 $16,239 - $23,200	4,000 New	4,000 $18,000
Q1 2021 May 10, 2021	SELL	$4.81 - $10.34 $24,049 - $51,700	-5,000 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$4.13 - $6.41 $20,650 - $32,050	-5,000 Reduced 50.0%	5,000 $24,000
Q3 2020 Nov 10, 2020	BUY	$4.82 - $7.72 $12,050 - $19,300	2,500 Added 33.33%	10,000 $58,000
Q2 2020 Aug 12, 2020	BUY	$5.69 - $9.69 $13,781 - $23,469	2,422 Added 47.7%	7,500 $51,000
Q1 2020 May 13, 2020	BUY	$3.77 - $11.0 $19,144 - $55,858	5,078 New	5,078 $32,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.